Vitality Watch

Dossier pubmed observational 02-nov-2026
Human cohort, case-control, or epidemiological association

Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.

Key claim: Dapagliflozin treatment was associated with an 87% reduction in the odds of progressing from prefrailty to frailty over one year in older hypertensive adults with chronic kidney disease.

Abstract

BACKGROUNDChronic kidney disease (CKD) and hypertension share common pathophysiological pathways contributing to vascular damage, endothelial dysfunction, and physical decline, particularly in older adults with prefrailty. To evaluate the relationship among renal injury, physical performance, and frailty progression in hypertensive older adults with CKD and assess whether dapagliflozin associates with reduced frailty progression, we designed the study DAPA-FORTRESS (DAPAgliflozin and Frailty prOgression in hypeRTension and chRonic kidnEy diSeaSe).METHODSWe enrolled 135 prefrail hypertensive patients with CKD aged >65 years and followed them for 1 year. After coarsened exact matching, our balanced cohort had 105 patients (52 dapagliflozin). Associations between albuminuria, estimated glomerular filtration rate (eGFR), and physical performance were analyzed using correlation and regression models. Effect of dapagliflozin on frailty progression was evaluated using multivariable logistic regression.RESULTSA significant inverse association between gait speed and albuminuria (r2 = 0.48, P < 0.0001) and significant positive linear association between gait speed and eGFR (r2 = 0.18; P < 0.0001) were observed. Patients with eGFR <60 mL/min/1.73 m2 exhibited significantly worse physical performance than those with higher eGFR (P = 0.0003). In adjusted analyses, receiving dapagliflozin was independently associated with lower odds of progressing to frailty at 1 year (OR = 0.130; CI 0.045-0.381; P < 0.001).CONCLUSIONIn older hypertensive patients with CKD, greater renal injury is associated with worse physical performance, while dapagliflozin use reduces the risk of frailty progression. These findings indicate a potential protective role of sodium-glucose cotransporter 2 inhibition in mitigating functional decline in this high-risk population.FUNDINGNIH: National Heart, Lung, and Blood Institute (R01-HL146691), National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK123259); American Heart Association (AHA- 24IPA1268813, AHA-22-915561, AHA-24-1195524).

Why this matters

[human-observational] This matched cohort adds a clinical frailty endpoint to the SGLT2 inhibitor evidence record, beyond model-based aging predictions, but does not establish prevention of frailty or extension of lifespan. [human-observational] The reported 87% lower odds cannot be interpreted as an equivalent reduction in absolute risk, and residual confounding remains possible. [human-rct] The existing null empagliflozin functional-capacity trial remains a contrasting result rather than being superseded, because the drug, population, and endpoint differ.

Source

Link

Briefing card

Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
Stage: observational · pubmed · 02-nov-2026

If you are an older adult with prefrailty, hypertension, and chronic kidney disease, this matched observational study linked dapagliflozin treatment to lower odds of becoming frail over one year, without establishing that the drug caused the difference.

Dapagliflozin treatment was associated with an 87% reduction in the odds of progressing from prefrailty to frailty over one year in older hypertensive adults with chronic kidney disease.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1172/JCI205416

build build 880 · 2bcef25 · 2026-11-18